Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | AKT2 | P31751 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 8/20 | 0.42 |
| ▸ | NPC1 | O15118 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2964666 | 0.79 | RAB9A (0.48) | AKT1AKT2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL477177 | 0.75 | DYRK1A (0.40) | AKT1AKT2DYRK1ARAB9ANPC1 | |
| SCHEMBL526690 | 0.75 | AKT1 (0.50) | AKT1AKT2DYRK1ARAB9ANPC1 | |
| SCHEMBL4790043 | 0.71 | RXFP1 (0.46) | RAB9ASMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL24165364 | 0.70 | DYRK1A (0.36) | DYRK1ARAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL12920736 | 0.70 | RAB9A (0.41) | AKT1AKT2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2646928 | 0.69 | GABRA1 (0.52) | DYRK1AKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL17640709 | 0.69 | PIK3CD (0.57) | AKT1AKT2DYRK1ARAB9ANPC1 | |
| SCHEMBL5056983 | 0.68 | RAB9A (0.54) | DYRK1ARAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL235881 | 0.67 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103384670-B | Imidazo [1, the 2-b] pyridazine replacing | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-05-25 | — | — | CN | disclosed |
| US-8987273-B2 | Substituted imidazo[1,2-B]pyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987273-B2 | Substituted imidazo[1,2-B]pyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987273-B2 | Substituted imidazo[1,2-B]pyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2598505-B1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-08-15 | — | — | US | disclosed |
| EP-2598505-A2 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012013713-A2 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210825-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES | NRAS, IDH2, NDUFB1 | AKT1 4494/4885AKT2 4136/4885DYRK1A 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.